Sarepta Losses Widens $SRPT $XHS

Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, has announced its financial results for the first quarter FY-2015.

The Results shows EPS went more worse from -$0.55 to -$1.15 YoY, while Revenues were $0 and Cash, cash equivalents and short-term investments went down to $ 166,223 from $ 210,344 YoY.

View the full earnings release here.